Skip to content

CYPH

CYPHERPUNK TECHNOLOGIES INC.

NASDAQ · Healthcare · Biotechnology · US

$2.53
−1.56%
Ask drillr

Year over year

Reported trailing growth

Revenue
-100.0%
EBITDA
+37.7%
EBIT
+81.4%
EPS
+137.3%
Free cash flow
+55.0%
Operating cash flow
+51.7%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+259.8%
EPS
-41.5%

Three-year CAGR

Revenue
—
EBITDA
+45.4%
EBIT
+47.8%
Net income
+107.1%
EPS
+104.0%
Free cash flow
+27.2%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026